home / stock / urov / urov message board
Subject | By | Source | When |
---|---|---|---|
EOY i believe | Grant Lee | investorshub | 11/16/2020 1:20:36 PM |
When's the FDA approval? | Warrens | investorshub | 11/15/2020 11:49:56 PM |
Wasn't expecting this until after FDA approval, looks | Grant Lee | investorshub | 11/13/2020 2:03:12 PM |
BINGO | Paullee | investorshub | 11/13/2020 1:38:51 PM |
Finally, Sumitomo, a japanese company, owns 75% of | Grant Lee | investorshub | 09/23/2020 6:02:20 PM |
While Urovant's vibegron is by far the superior | Grant Lee | investorshub | 09/23/2020 5:55:13 PM |
Astellas' myrbetriq achieved $900 MM of sales within | Grant Lee | investorshub | 09/23/2020 5:43:29 PM |
As Astellas' Mirabegron (myrbetriq) is closing in on | Grant Lee | investorshub | 09/23/2020 5:35:03 PM |
C C transcript | Paullee | investorshub | 06/20/2020 8:54:39 PM |
Urovant Sciences Announces Collaboration with Sunovion Pharmaceuticals | Paullee | investorshub | 06/18/2020 12:59:37 PM |
Jefferies presentation | Paullee | investorshub | 06/02/2020 2:52:08 PM |
News, Short Squeeze, Breakout and More Instantly...
Urovant Sciences Ltd. Company Name:
UROV Stock Symbol:
NASDAQ Market:
Interim 12-week analysis from a Phase 2a trial of the potential gene therapy, URO-902, in women with overactive bladder (OAB) and urge urinary incontinence (UUI) will be featured in a late breaker presentation by Kenneth M. Peters, M.D. during Friday morning’s plenary session...
Study showed clinically meaningful impact on common symptoms of overactive bladder (OAB) compared to placebo from baseline to week 12 Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced positive topline results from its Phase 2a, double-...
Data from the 12-week EMPOWUR trial regarding patient perceptions of improvement of OAB symptoms show that significantly more patients treated once-daily with GEMTESA ® (vibegron) experienced patient-perceived improvements due to the reduction in micturition frequency (urin...